v3.26.3
Segment Information
 12 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has one reportable segment: R&D of the use of psychedelic medicine and drug therapies.
The accounting policies of the psychedelic medicine and drug therapies segment are consistent with those described in Note 2, Basis of Presentation and Summary of Significant Accounting Policies, and the measure of segment assets is reported on the balance sheets as total assets. The Company’s CODM is the Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. Operating expenses is assessed by the CODM to make decisions on how to allocate resources, such as determining additional costs for preclinical and clinical development of the Company’s product candidates.

The following table summarized significant segment expenses for the years ended June 30, 2026 and 2025:

Psychedelic Medicine and Drug Therapies Segment
June 30,
2026		June 30,
2025
(in thousands)
Research and development expenses(5,210)(10,747)
General and administration expenses (excluding stock-based payment)(10,018)(10,273)
Stock-based payment(7,559)(2,609)
Financing expense(883)(24,563)

Material segment income mainly consists of R&D tax incentive amounted to $4.7 million and $1.8 million for the fiscal years ended June 30, 2026 and 2025, respectively.